Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

o osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other then statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of futu
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
(Date:5/27/2015)...  Precision Advisors ( www.precisionadvisors.com ), a Precision for ... Trends Study of 145 managed care executives. The study ... of big data and predictive analytics, but are not ... Health Information Technology for Economic and Clinical Health Act ... of electronic medical records (EMRs) by 2014. While a ...
(Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... New Somatropin Formulation Demonstrate Advantages ... Over Existing Once-Daily ... Nottingham, UK-based speciality pharmaceuticals,company, today announced that the successful ... the synthetic human growth,hormone (hGH) somatropin. Trials demonstrated therapeutic ...
... released by The Philadelphia AIDS Consortium:, WHO: ... its network of eleven (11) community-based organization,sites located ... 30 AmeriCorps ACTS members working throughout New,Jersey, Delaware ... 9 a.m. until Noon; Media Focused,Event 10:30 - ...
Cached Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
(Date:5/27/2015)... Arizona (PRWEB) May 27, 2015 Continuing ... mission of healthier patients in the community, SmartPractice® ... Center (formerly John C. Lincoln). SmartPractice Vice President of ... Michelle Shaw presented a $25,000 check to Paulla Miller, ... HonorHealth’s Breast Health & Research Center on April 30. ...
(Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
(Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Million in Compensation and Benefits, MINNEAPOLIS, Dec. 6 ... William McGuire, today agreed to,terms with the UnitedHealth Special ... than $420 million in stock options and other,compensation to ... during,his tenure as CEO of the company, in addition ...
... against colorectal, prostate and oral tumors , , THURSDAY, ... from black raspberries, a fruit beverage and old-fashioned ... to treat or prevent different types of cancer, ... not been considered good treatments for chronic illness, ...
... Inc. (NYSE: WPI ), a leading ... reached a settlement with Novartis,Pharmaceuticals Corporation, Novartis ... and Proterra AG (collectively,"Novartis") on outstanding patent ... (rivastigmine tartrate) capsules., Under the terms ...
... (Nasdaq: NBIX ) announced today that the ... Veralliance Properties for its real estate,assets. Total consideration ... Concurrently with the closing of the transaction, Neurocrine,leased ... term, with renewal,options. Neurocrine also has certain options ...
... EXEL ) announced today that that it will hold ... of Hematology,48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ... webcast and may be accessed in the Event Calendar,page under ... -- Michael Morrissey, PhD, President of Research & Development ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
Cached Medicine News:Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3Health News:Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation 2Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: